Nanomedicine : nanotechnology, biology, and medicine最新文献

{"title":"Corrigendum to “a state-of-the-art review on inhalable nanoconjugates for targeted drug delivery in acute lung injury: Advances, challenges and future directions” [nanomedicine: Nanotechnology, biology and medicine, volume 70, November 2025, 102873]","authors":"Piyushkumar Sadhu , Mamta Kumari , Nirmal Shah , Niyati Shah , Chitrali Talele , Falguni Rathod","doi":"10.1016/j.nano.2025.102883","DOIUrl":"10.1016/j.nano.2025.102883","url":null,"abstract":"","PeriodicalId":19050,"journal":{"name":"Nanomedicine : nanotechnology, biology, and medicine","volume":"71 ","pages":"Article 102883"},"PeriodicalIF":4.6,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145636522","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Enhancing intratumoral spread of radioluminescent nanoparticles via collagenase functionalization for radiation-induced photodynamic cancer therapy","authors":"Sung-Ho Shin ,&nbsp;Dhushyanth Viswanath ,&nbsp;Haley A. Harper ,&nbsp;Sandra E. Torregrosa-Allen ,&nbsp;Carli J. McMahan ,&nbsp;Alex E. Schwimmer ,&nbsp;Bennett D. Elzey ,&nbsp;You-Yeon Won","doi":"10.1016/j.nano.2025.102879","DOIUrl":"10.1016/j.nano.2025.102879","url":null,"abstract":"<div><div>Radioluminescent nanoparticles enable radiotherapy- or X-ray-triggered photodynamic therapy (RT-PDT, also referred to as X-PDT in the literature) using the 5-aminolevulinic acid (ALA) prodrug, thereby overcoming the limited tissue penetration of conventional PDT. However, their therapeutic efficacy remains constrained by poor intratumoral nanoparticle distribution. To address this challenge, we developed collagenase-functionalized calcium tungstate nanoparticles capable of enzymatically degrading the extracellular matrix (ECM) in solid tumors. Micro-CT imaging revealed that collagenase functionalization increased intratumoral nanoparticle distribution by approximately sevenfold. <em>In vivo</em> studies further showed that enhanced penetration improved NP delivery, but that surface-bound maleimide linkers and collagenase partially scavenged reactive oxygen species (ROS), revealing a trade-off between ECM degradation and the quenching of ROS-mediated photodynamic effects. Overall, these findings demonstrates that collagenase-functionalized radioluminescent nanoparticles can effectively overcome stromal barriers in collagen-rich solid tumors, providing a promising strategy for next-generation RT-PDT while underscoring the importance of balancing enzymatic ECM remodeling with preservation of ROS generation.</div></div>","PeriodicalId":19050,"journal":{"name":"Nanomedicine : nanotechnology, biology, and medicine","volume":"71 ","pages":"Article 102879"},"PeriodicalIF":4.6,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145605120","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"RGD-Lipo@GOx: A nanotherapeutic strategy for targeting glycolysis and immune evasion in triple-negative breast cancer","authors":"Chao Zhu,&nbsp;Chenxu Guo,&nbsp;Ligong Zhang,&nbsp;Jun Qian,&nbsp;Mingliang Zhang","doi":"10.1016/j.nano.2025.102889","DOIUrl":"10.1016/j.nano.2025.102889","url":null,"abstract":"<div><div>Triple-negative breast cancer (TNBC) is a highly aggressive malignancy driven by glycolysis and immune evasion, with limited therapeutic options. This study develops RGD-modified glucose oxidase-loaded liposomes (RGD-Lipo@GOx) to target TNBC by modulating the MIF/NR3C2 axis, aiming to inhibit glycolysis and remodel the immune microenvironment. RGD-Lipo@GOx exhibited high encapsulation efficiency and tumor specificity. Bioinformatics analyses confirmed upregulated MIF and downregulated NR3C2 in TNBC. <em>In vitro</em>, RGD-Lipo@GOx suppressed glycolysis, migration, and invasion in MDA-MB-231 and BT-549 cells, upregulating NR3C2 and inhibiting MIF and PI3K/AKT signaling. <em>In vivo</em>, a TNBC xenograft model demonstrated enhanced tumor targeting, significant growth inhibition, and reduced glycolysis without systemic toxicity. These results highlight RGD-Lipo@GOx's potential as a nanotherapeutic platform that disrupts TNBC's metabolic and immune evasion mechanisms. Its high efficacy and safety suggest potential for clinical translation, particularly in combination with immunotherapies, and applicability to other glycolysis-driven cancers, advancing nanomedicine for precision oncology.</div></div>","PeriodicalId":19050,"journal":{"name":"Nanomedicine : nanotechnology, biology, and medicine","volume":"71 ","pages":"Article 102889"},"PeriodicalIF":4.6,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145751935","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Protein-based biomaterials: Advances in structural design for drug delivery and regenerative medicine","authors":"Muhammad Sohail ,&nbsp;Mahtab Mirbolouk","doi":"10.1016/j.nano.2025.102875","DOIUrl":"10.1016/j.nano.2025.102875","url":null,"abstract":"<div><div>The beneficial physical, chemical, and biological properties of proteins make them useful building blocks in the construction of biomedicals and nanomaterials. There are various biomaterials to develop inventive drug delivery systems ranging from simple to complex proteins which can be more efficient for patients undergoing surgical procedures. In the line of this article, the definition of medicine via proteins is based on complex bioengineering systems that mix tailored biomaterials with molecular algorithms to form controlled bioactive nanosystems. Among biomaterials, proteins are unique, because they can be found directly in nature, which qualify them easy for use, especially in surgical procedures. This article is aimed at describing their origin, structural properties, functions characteristics of interest in biology, and activity as drug delivery systems. Their native form and form of biomaterials i.e., hydrogels, scaffolds, membranes, fibers, and nanoparticles are examined. The article discusses novel designed nanoarchitectures aimed to solve long lasting problems in drug delivery like poor drug solubility, low bioavailability, and encapsulation of active pharmaceutical ingredients (APIs). The most important innovations are systems that respond to stimuli, mucoadhesive and mucus penetrating structures, lymphatic-targeting designs, and carriers that respond to environmental changes. Moreover, the article outlines the therapeutic uses of biomaterials based on proteins in tissue engineering (bone, cartilage, skin, cardiac, and neural tissue engineering), cancer treatment, diabetes, gene therapy, and in the treatment of inflammatory and chronically symptomatic disorders. Each part is arranged to minimize overlap and highlight functional distinctiveness to provide a cohesive design that integrates structure, function, and use. The review ends with the discussion of the existing gaps and the proposed pathways for future investigations which could facilitate the clinical translation of the work. This work serves as a stimulus toward the rational conception of protein-based materials and designed nanocarriers which are structurally tailored and application-driven, increasing their impact in the fields of drug delivery and regenerative medicine.</div></div>","PeriodicalId":19050,"journal":{"name":"Nanomedicine : nanotechnology, biology, and medicine","volume":"71 ","pages":"Article 102875"},"PeriodicalIF":4.6,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145479128","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Nanoparticle distribution in the central nervous system following intrathecal administration: A multi-modal analysis of lumbar versus cisterna magna routes","authors":"Oluwatobi H. Babayemi ,&nbsp;Corinne Fotso ,&nbsp;Sauradip Chaudhuri ,&nbsp;Lindsey K. Sablatura ,&nbsp;Cassandra Baker ,&nbsp;Fred Christian Velasquez ,&nbsp;Janelle Morton ,&nbsp;Eva Sevick-Muraca ,&nbsp;Rachael W. Sirianni","doi":"10.1016/j.nano.2025.102877","DOIUrl":"10.1016/j.nano.2025.102877","url":null,"abstract":"<div><div>Intrathecal drug delivery refers to the direct administration of compounds to cerebrospinal fluid (CSF), which can enhance delivery to the central nervous system (CNS) while minimizing peripheral exposure. Our prior work demonstrated that 100 nm, solid polystyrene nanoparticles surface modified with poly(ethylene glycol) (PEG) distribute within the CNS after intrathecal administration via the cisterna magna route (IT-CM). Here, we focus on comparing nanoparticle fate following administration to IT CM versus lumbar (IT-L) access points. We utilized dynamic a variety of imaging techniques to track the movement of model, ⁶⁴Cu-radiolabeled, fluorescent nanoparticles, hypothesizing that the IT-CM route would enable greater brain-localized delivery of nanoparticles when compared with the IT-L route. Spatiotemporal patterns of nanoparticle distribution and clearance were studied through a combination of quantitative positron emission tomography/computer tomography (PET/CT), fluorescent imaging (confocal microscopy), and biodistribution experiments (liquid scintillation counting). These studies revealed that: (1) the IT-CM route yielded greater brain-wide nanoparticle delivery while the IT-L route yielded greater spinal delivery, (2) the IT-CM route resulted in sustained retention of nanoparticles within the CNS and proximal lymphatics while the IT-L route resulted in higher nanoparticle clearance to peripheral organs, and (3) both the IT-CM and IT-L routes resulted in detectable though incomplete parenchymal delivery of nanoparticles, with the majority of signal remaining confined to the subarachnoid space. These findings underscore the pivotal role of intrathecal location in influencing nanoparticle biodistribution and clearance pathways within the CNS, identifying access point as an important design parameter when optimizing nanomedicine for intrathecal drug delivery.</div></div>","PeriodicalId":19050,"journal":{"name":"Nanomedicine : nanotechnology, biology, and medicine","volume":"71 ","pages":"Article 102877"},"PeriodicalIF":4.6,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145636502","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"PapMV nanoparticles: A novel pathway to SARS-CoV-2 protection, distinct from Imidazoquinolines","authors":"Marilène Bolduc ,&nbsp;Philippe Saint-Louis ,&nbsp;Damien Carignan ,&nbsp;Caroline Garneau ,&nbsp;Yann Breton ,&nbsp;Martin Pelletier ,&nbsp;Anne Rancourt ,&nbsp;Masahiko S. Satoh ,&nbsp;Sachiko Sato ,&nbsp;Mégan Gilbert ,&nbsp;Henintsoa Rabezanahary ,&nbsp;Mariana Baz ,&nbsp;Isabelle Dubuc ,&nbsp;Louis Flamand ,&nbsp;Denis Leclerc","doi":"10.1016/j.nano.2025.102887","DOIUrl":"10.1016/j.nano.2025.102887","url":null,"abstract":"<div><div>Toll-like receptor (TLR) 7/8 agonists, such as imidazoquinoline derivatives (IMDs), hold great potential as immune modulators that can boost innate antiviral and anticancer immunity. However, significant challenges persist in achieving sufficient efficacy while minimizing toxic side effects. To date, only imiquimod (IMQ) has received FDA approval, and its use is restricted to topical applications. Therefore, there is a significant need for novel and safe TLR 7/8 agonists. In response to this, we developed a new generation of TLR7/8 agonist, the PapMV nanoparticle (PapMV nano). IMDs and PapMV nano are both innate immune system-activating drugs that have demonstrated antiviral and anticancer activities, but they differ significantly in three key aspects: (1) composition (proteins and ssRNA for PapMV nano vs. synthetic molecules for IMDs), (2) structure (large nanoparticles vs. small molecules), and (3) the mechanism of cell entry (internalization for PapMV nano vs. cell diffusion for IMDs). To compare how immune cells react to these two types of drug products, we studied cell motility, cell metabolism, and the induction of apoptosis in human monocyte-derived macrophages (hMDMs). Our data reveal that PapMV nano enhances motility and mitochondrial respiration while decreasing glycolysis, whereas IMDs have no impact on motility and mitochondrial respiration but increase glycolysis. PapMV nano is also the only agonist that does not induce apoptosis. Although the cellular responses to these two types of agonists differ strikingly, both are capable of eliciting antiviral immunity. We confirmed this potential for PapMV nano by demonstrating its capacity to prevent SARS-CoV-2 infection, supporting its utilization as a safe and effective immune modulator, capable of providing broad protection against respiratory viruses.</div></div>","PeriodicalId":19050,"journal":{"name":"Nanomedicine : nanotechnology, biology, and medicine","volume":"71 ","pages":"Article 102887"},"PeriodicalIF":4.6,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145701419","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Corrigendum to “The diosgenin prodrug nanoparticles with pH-responsive as a drug delivery system uniquely prevents thrombosis without increased bleeding risk” [Nanomed: Nanotechnol Biol Med (April 2018) volume 14, issue 3, pages 673–684]","authors":"Zeliang Wei PhD ,&nbsp;Guang Xin PhD ,&nbsp;Haibo Wang PhD ,&nbsp;Huajie Zheng MS ,&nbsp;Chengjie Ji PhD ,&nbsp;Jun Gu MD ,&nbsp;Limei Ma PhD ,&nbsp;Chaoyi Qin MD ,&nbsp;Zhihua Xing BS ,&nbsp;Hai Niu PhD ,&nbsp;Wen Huang PhD","doi":"10.1016/j.nano.2025.102892","DOIUrl":"10.1016/j.nano.2025.102892","url":null,"abstract":"","PeriodicalId":19050,"journal":{"name":"Nanomedicine : nanotechnology, biology, and medicine","volume":"71 ","pages":"Article 102892"},"PeriodicalIF":4.6,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145846315","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Zirconium oxide nanoparticles in advancing photodynamic therapy for cancer treatment","authors":"Alshayma N. Al-Thani ,&nbsp;Asma Ghafoor Jan ,&nbsp;Zainab Hajialthakar ,&nbsp;Nada Aakel ,&nbsp;Mohamed Abbas","doi":"10.1016/j.nano.2025.102876","DOIUrl":"10.1016/j.nano.2025.102876","url":null,"abstract":"<div><div>This review delves into the intricacies of Photodynamic Therapy (PDT), focusing on mechanisms such as the accumulation of selective photosensitizers and the generation of Reactive Oxygen Species (ROS). Research is investigating the use of zirconium oxide nanoparticles (ZrO₂ NPs) and their combination with upconversion nanoparticles. The functionalization of ZrO₂ NPs is stressed for targeted drug administration and enhanced therapeutic effects. Addressing PDT challenges, ZrO₂ NPs exhibit potential to enhance treatment accuracy, minimize side effects, and improve overall success. Supported by preclinical and clinical research, zirconium-based PDT emerges as a transformative cancer therapy technique. Integrating ZrO₂ NPs into PDT represents a groundbreaking approach, allowing selective cancer cell targeting and promising improved treatment outcomes and synergies with other modalities. With demonstrated safety and efficacy, ZrO₂ PDT constitutes a vital component in advancing cancer patient outcomes globally.</div></div>","PeriodicalId":19050,"journal":{"name":"Nanomedicine : nanotechnology, biology, and medicine","volume":"71 ","pages":"Article 102876"},"PeriodicalIF":4.6,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145513303","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Combination of lactoferrin-based microparticles and carboanhydrase II inhibitor demonstrates enhanced inhibition effect on Ewing sarcoma cells","authors":"Sergei Voloshin ,&nbsp;Artem Antoshin ,&nbsp;Denis Aniskin ,&nbsp;Kamilla Antoshina ,&nbsp;Yuri Efremov ,&nbsp;Nadezhda Aksenova ,&nbsp;Olga Romantsova ,&nbsp;Darya Fayzullina ,&nbsp;Anton Shetnev ,&nbsp;Elena Sadchikova ,&nbsp;Peter Timashev ,&nbsp;Ilya Ulasov","doi":"10.1016/j.nano.2025.102897","DOIUrl":"10.1016/j.nano.2025.102897","url":null,"abstract":"<div><div>Ewing sarcoma (ES) is a highly aggressive pediatric malignancy with limited treatment options and frequent development of drug resistance. In this case, novel drug delivery systems may overcome tumor resistance and improve therapeutic efficacy. We developed lactoferrin–chondroitin sulfate microparticles (Lf-ChS MPs) that can be loaded with the carbonic anhydrase II inhibitor OX72. Their physicochemical properties were characterized by AFM, FTIR, zeta potential, DSC/TGA, and drug release assays. In vitro cytotoxicity was evaluated in ES cell lines (A673, ES36, T69, and doxorubicin-resistant A673 cells), with 977hTERT fibroblasts as controls. Drug encapsulation significantly enhanced the antiproliferative activity of OX72 in ES36 and A673 cells, as well as in doxorubicin-resistant cells. Mechanistically, Lf-ChS-OX72 reduced FTH1 expression, indicating ferroptosis induction, with no influence on apoptosis. Lf-ChS microparticles provide a promising platform for OX72 delivery inducing ferroptosis-mediated cytotoxicity in doxorubicin-resistant sarcoma cells.</div></div>","PeriodicalId":19050,"journal":{"name":"Nanomedicine : nanotechnology, biology, and medicine","volume":"71 ","pages":"Article 102897"},"PeriodicalIF":4.6,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145900675","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Tailored iron oxide nanoparticles for biomedical applications: Hydroxyethyl starch coating enhances endothelial biocompatibility","authors":"Lydia-Nefeli Thrapsanioti ,&nbsp;Andrey N. Kuskov ,&nbsp;Aikaterini Berdiaki ,&nbsp;Anna L. Luss ,&nbsp;Elizaveta R. Vlaskina ,&nbsp;Anna V. Ivanova ,&nbsp;Maxim A. Abakumov ,&nbsp;Maria Marmara ,&nbsp;Kalliope Plexousaki ,&nbsp;Aristides Tsatsakis ,&nbsp;Dragana Nikitovic","doi":"10.1016/j.nano.2025.102880","DOIUrl":"10.1016/j.nano.2025.102880","url":null,"abstract":"<div><div>Iron oxide nanoparticles (IONPs) offer promise for drug delivery and imaging, but their vascular safety requires thorough evaluation. Hydroxyethyl starch (HES) is a clinically used, biocompatible polysaccharide with potential as a nanoparticle coating to improve vascular safety. We synthesized novel hydroxyethyl starch-coated IONPs (IONPs@HES) and assessed their properties and effects on human microvascular endothelial cells (HMEC-1) under basal and inflammatory conditions. IONPs@HES showed magnetite cores, near-neutral charge, and reduced magnetic saturation, supporting biocompatibility. They were efficiently internalized without affecting viability or proliferation (20–500 μg/mL) and did not increase LPS-induced ICAM-1 expression. Autophagic activity, assessed by LC3 immunofluorescence and Cyto-ID flow cytometry, remained unchanged, suggesting preserved autophagic homeostasis. A modest increase in phosphorylated caveolin-1 (p-CAV1) was observed, with no enhancement under LPS stimulation. Co-treatment with indomethacin showed no additive toxicity. These findings support IONPs@HES as a biocompatible nanoplatform suitable for vascular-targeted cancer therapy, meriting further in vivo validation.</div></div>","PeriodicalId":19050,"journal":{"name":"Nanomedicine : nanotechnology, biology, and medicine","volume":"71 ","pages":"Article 102880"},"PeriodicalIF":4.6,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145577788","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}